Evidence map›Paper›PMID 41322563›Full record

ArticleACS omega2025

Rational Design and Greener Synthesis of Selenylated Indolamides as Potential Anti-Alzheimer's Agents.

Angélica Justino Dias, Aldo Sena Oliveira, Angélica Ceci Silva, Antonio Luiz Braga

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Angélica Justino DiasDepartment of Chemistry, Center for Physical and Mathematical Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88040-900, Brazil.ORCID https://orcid.org/0000-0003-3076-7248
Aldo Sena OliveiraFaculty of Medicine, University of Lisbon, Gulbenkian Institute for Molecular Medicine (GIMM), Lisbon 1649-028, Portugal.ORCID https://orcid.org/0000-0001-7760-4484
Angélica Ceci SilvaDepartment of Chemistry, Center for Physical and Mathematical Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88040-900, Brazil.ORCID https://orcid.org/0000-0002-7286-9720
Antonio Luiz BragaDepartment of Chemistry, Center for Physical and Mathematical Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina 88040-900, Brazil.ORCID https://orcid.org/0000-0001-9903-6764

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study presents the rational design and sustainable synthesis of selenylated indolamides as potential therapeutic agents for Alzheimer's disease. Through computational approaches, including molecular docking and pharmacokinetic analyses, we identified key structural modifications that improve acetylcholinesterase inhibition, a critical target for AD treatment. We employed an environmentally benign I

Identifiers

PMID41322563
PMCPMC12658801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.